Last reviewed · How we verify
Poteligeo (MOGAMULIZUMAB)
Poteligeo works by binding to the C-C chemokine receptor type 4, which is involved in the migration and proliferation of T-cells.
Poteligeo (Mogamulizumab) is a chemokine receptor type 4 interaction drug developed by Kyowa Kirin. It targets the C-C chemokine receptor type 4 and is used to treat mycosis fungoides, peripheral T-cell lymphoma, and primary cutaneous T-cell lymphoma. Poteligeo was FDA-approved in 2018 and has a half-life of 17 days. It is a small molecule modality and remains patented. Key safety considerations include potential infusion reactions and cytopenias.
At a glance
| Generic name | MOGAMULIZUMAB |
|---|---|
| Sponsor | Kyowa Kirin |
| Drug class | Chemokine Receptor Type 4 Interaction [EPC] |
| Target | C-C chemokine receptor type 4 |
| Modality | Monoclonal antibody |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 2018 |
| Annual revenue | 300 |
Mechanism of action
Mogamulizumab-kpkc is defucosylated, humanized IgG1 kappa monoclonal antibody that binds to CCR4, G protein-coupled receptor for CC chemokines that is involved in the trafficking of lymphocytes to various organs. Non-clinical in vitro studies demonstrate mogamulizumab-kpkc binding targets cell for antibody-dependent cellular cytotoxicity (ADCC) resulting in depletion of the target cells. CCR4 is expressed on the surface of some T-cell malignancies and is expressed on regulatory T-cells (Treg) and subset of Th2 T-cells.
Approved indications
- Mycosis fungoides
- Peripheral T-cell lymphoma
- Primary cutaneous T-cell lymphoma
Common side effects
- Rash
- Infusion related reactions
- Fatigue
- Diarrhea
- Musculoskeletal pain
- Upper respiratory tract infection
- Skin infection
- Pyrexia
- Edema
- Nausea
- Thrombocytopenia
- Anemia
Key clinical trials
- A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1 (PHASE2)
- Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT) (EARLY_PHASE1)
- Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma (PHASE1)
- Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas (PHASE2)
- Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma (PHASE2)
- Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma
- Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment (PHASE1,PHASE2)
- Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Poteligeo CI brief — competitive landscape report
- Poteligeo updates RSS · CI watch RSS
- Kyowa Kirin portfolio CI